Mitochondria ubiquitin ligase, MARCH5 resolves hepatitis B virus X protein aggregates in the liver pathogenesis

Area of Science:

• Hepatology
• Molecular Biology
• Oncology

Background:

• Hepatitis B virus (HBV) infection is a major cause of chronic liver disease and hepatocellular carcinoma (HCC).
• The hepatitis B viral x (HBx) protein is implicated in HCC pathogenesis, making its negative regulation a therapeutic goal.
• Mitochondrial E3 ubiquitin ligase MARCH5 is explored for its role in HBV-related liver disease.

Purpose of the Study:

• To investigate the role of MARCH5 in the degradation of the hepatitis B viral x (HBx) protein.
• To determine the correlation between MARCH5 expression levels and patient survival in HCC.
• To elucidate the mechanism by which MARCH5 regulates HBx and its downstream effects.

Main Methods:

• Correlation analysis of MARCH5 expression with HCC patient survival.
• Co-immunoprecipitation to assess MARCH5-HBx interaction.
• Western blotting to evaluate protein levels and degradation.
• Analysis of protein aggregate formation using semi-denaturing detergent agarose gel electrophoresis.
• Assessment of reactive oxygen species (ROS) production, mitophagy, and cyclooxygenase-2 (COX-2) gene expression.

Main Results:

• High MARCH5 expression levels correlate with improved survival in HCC patients.
• MARCH5 interacts with HBx in mitochondria and targets it for proteasomal degradation.
• The N-terminal RING domain of MARCH5 is crucial for HBx interaction, while its E3 ligase activity is necessary for HBx degradation.
• MARCH5 mediates the elimination of HBx-induced protein aggregates.
• MARCH5 suppresses HBx-induced ROS production, mitophagy, and COX-2 gene expression.

Conclusions:

• MARCH5 plays a critical role in degrading the oncogenic HBx protein.
• MARCH5 expression is a favorable prognostic marker in HCC patients.
• MARCH5 represents a potential therapeutic target for mitigating HBV-mediated liver disease pathogenesis.